{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T17:37:16Z","timestamp":1794937036197,"version":"4.9.1"},"reference-count":154,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1016\/j.neuropharm.2021.108880","type":"journal-article","created":{"date-parts":[[2021,11,10]],"date-time":"2021-11-10T01:48:53Z","timestamp":1636508933000},"page":"108880","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"special_numbering":"C","title":["Current concepts in treating mild cognitive impairment in Parkinson's disease"],"prefix":"10.1016","volume":"203","author":[{"given":"Jay S.","family":"Schneider","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3532-8669","authenticated-orcid":false,"given":"Sandhya","family":"Kortagere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuropharm.2021.108880_bib1","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/S1474-4422(17)30170-9","article-title":"A new tool to identify patients with Parkinson's disease at increased risk of dementia","volume":"16","author":"Aarsland","year":"2017","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.neuropharm.2021.108880_bib2","first-page":"234","article-title":"Efficacy of rivastigmine for cognitive symptoms in Parkinson disease with dementia","volume":"15","author":"Almaraz","year":"2009","journal-title":"Neurol."},{"key":"10.1016\/j.neuropharm.2021.108880_bib3","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1007\/s00213-019-05296-y","article-title":"Dopamine D2-like receptor stimulation blocks negative feedback in visual and spatial reversal learning in the rat: behavioural and computational evidence","volume":"236","author":"Alsio","year":"2019","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.neuropharm.2021.108880_bib4","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.jns.2015.06.037","article-title":"Cognitive and neuroanatomical correlates of neuropsychiatric symptoms in Parkinson's disease: a systematic review","volume":"356","author":"Alzahrani","year":"2015","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.neuropharm.2021.108880_bib5","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1111\/j.1471-4159.1992.tb09752.x","article-title":"Comparative alterations of nicotinic and muscarinic binding sites in Alzheimer's and Parkinson's diseases","volume":"58","author":"Aubert","year":"1992","journal-title":"J. Neurochem."},{"key":"10.1016\/j.neuropharm.2021.108880_bib6","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/j.neurobiolaging.2009.10.018","article-title":"Dopamine D(1) receptors and age differences in brain activation during working memory","volume":"32","author":"Backman","year":"2011","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.neuropharm.2021.108880_bib7","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/j.neubiorev.2006.06.005","article-title":"The correlative triad among aging, dopamine, and cognition: current status and future prospects","volume":"30","author":"Backman","year":"2006","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/j.neuropharm.2021.108880_bib8","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1002\/mds.27962","article-title":"NYX-458 improves cognitive performance in a primate Parkinson's disease model","volume":"35","author":"Barth","year":"2020","journal-title":"Mov. Disord. : official journal of the Movement Disorder Society"},{"key":"10.1016\/j.neuropharm.2021.108880_bib9","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1016\/S0306-4522(99)00065-2","article-title":"Effects of dopamine depletion of the dorsal striatum and further interaction with subthalamic nucleus lesions in an attentional task in the rat","volume":"92","author":"Baunez","year":"1999","journal-title":"Neuroscience"},{"key":"10.1016\/j.neuropharm.2021.108880_bib10","doi-asserted-by":"crossref","first-page":"2558","DOI":"10.1093\/brain\/awz193","article-title":"Locus coeruleus imaging as a biomarker for noradrenergic dysfunction in neurodegenerative diseases","volume":"142","author":"Betts","year":"2019","journal-title":"Brain : J. Neurol."},{"key":"10.1016\/j.neuropharm.2021.108880_bib11","doi-asserted-by":"crossref","first-page":"e245","DOI":"10.1038\/tp.2013.22","article-title":"Association of dopamine-related genetic loci to dopamine D3 receptor antagonist ABT-925 clinical response","volume":"3","author":"Bhathena","year":"2013","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.neuropharm.2021.108880_bib12","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s10072-018-3628-3","article-title":"Efficacy of safinamide on non-motor symptoms in a cohort of patients affected by idiopathic Parkinson's disease","volume":"40","author":"Bianchi","year":"2019","journal-title":"Neurol. Sci."},{"key":"10.1016\/j.neuropharm.2021.108880_bib13","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/j.bbr.2009.12.048","article-title":"The cholinergic system and Parkinson disease","volume":"221","author":"Bohnen","year":"2011","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.neuropharm.2021.108880_bib14","first-page":"2171","volume":"vol. 41","author":"Borchert","year":"2016"},{"key":"10.1016\/j.neuropharm.2021.108880_bib15","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1152\/physrev.00049.2017","article-title":"Pharmacology of adenosine receptors: the state of the art","volume":"98","author":"Borea","year":"2018","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.neuropharm.2021.108880_bib16","doi-asserted-by":"crossref","first-page":"2152","DOI":"10.1111\/j.1460-9568.1997.tb01382.x","article-title":"The primate striatum: neuronal activity in relation to spatial attention versus motor preparation","volume":"9","author":"Boussaoud","year":"1997","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.neuropharm.2021.108880_bib17","doi-asserted-by":"crossref","first-page":"2042","DOI":"10.1002\/mds.21065","article-title":"Stanley Fahn Lecture 2005: the staging procedure for the inclusion body pathology associated with sporadic Parkinson's disease reconsidered","volume":"21","author":"Braak","year":"2006","journal-title":"Mov. Disord. : official journal of the Movement Disorder Society"},{"key":"10.1016\/j.neuropharm.2021.108880_bib18","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.jns.2006.05.011","article-title":"Cognitive decline correlates with neuropathological stage in Parkinson's disease","volume":"248","author":"Braak","year":"2006","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.neuropharm.2021.108880_bib19","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1002\/mds.27246","article-title":"Transcranial magnetic stimulation does not improve mild cognitive impairment in Parkinson's disease","volume":"33","author":"Buard","year":"2018","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neuropharm.2021.108880_bib20","doi-asserted-by":"crossref","first-page":"81","DOI":"10.3389\/fnhum.2014.00081","article-title":"Changes in GABA and glutamate concentrations during memory tasks in patients with Parkinson's disease undergoing DBS surgery","volume":"8","author":"Buchanan","year":"2014","journal-title":"Front. Hum. Neurosci."},{"key":"10.1016\/j.neuropharm.2021.108880_bib21","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1185\/030079902125000813","article-title":"Rivastigmine for the treatment of dementia and visual hallucinations associated with Parkinson's disease: a case series","volume":"18","author":"Bullock","year":"2002","journal-title":"Curr. Med. Res. Opin."},{"key":"10.1016\/j.neuropharm.2021.108880_bib22","doi-asserted-by":"crossref","first-page":"2695","DOI":"10.1007\/s00213-020-05566-0","article-title":"Novel, non-nitrocatechol catechol-O-methyltransferase inhibitors modulate dopamine neurotransmission in the frontal cortex and improve cognitive flexibility","volume":"237","author":"Byers","year":"2020","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.neuropharm.2021.108880_bib23","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1016\/j.neuropsychologia.2006.03.030","article-title":"Reversal learning in Parkinson's disease depends on medication status and outcome valence","volume":"44","author":"Cools","year":"2006","journal-title":"Neuropsychologia"},{"key":"10.1016\/j.neuropharm.2021.108880_bib24","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1093\/cercor\/11.12.1136","article-title":"Enhanced or impaired cognitive function in Parkinson's disease as a function of dopaminergic medication and task demands","volume":"11","author":"Cools","year":"2001","journal-title":"Cerebr. Cortex"},{"key":"10.1016\/j.neuropharm.2021.108880_bib25","doi-asserted-by":"crossref","first-page":"e113","DOI":"10.1016\/j.biopsych.2011.03.028","article-title":"Inverted-U-shaped dopamine actions on human working memory and cognitive control","volume":"69","author":"Cools","year":"2011","journal-title":"Biol. Psychiatr."},{"key":"10.1016\/j.neuropharm.2021.108880_bib26","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1038\/sj.npp.1301153","article-title":"L-DOPA disrupts activity in the nucleus accumbens during reversal learning in Parkinson's disease","volume":"32","author":"Cools","year":"2007","journal-title":"Neuropsychopharmacology: official publication of the American College of Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2021.108880_bib27","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1111\/j.1460-9568.2011.07815.x","article-title":"Effects of the alpha-2 adrenoceptor agonist guanfacine on attention and working memory in aged non-human primates","volume":"34","author":"Decamp","year":"2011","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.neuropharm.2021.108880_bib28","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1136\/jnnp-2011-301817","article-title":"Dysfunction of the locus coeruleus-norepinephrine system and related circuitry in Parkinson's disease-related dementia","volume":"84","author":"Del Tredici","year":"2013","journal-title":"J. Neurol. Neurosurg. Psychiatr."},{"key":"10.1016\/j.neuropharm.2021.108880_bib29","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1007\/s00415-006-0175-2","article-title":"Utility of the Mattis dementia rating scale to assess the efficacy of rivastigmine in dementia associated with Parkinson's disease","volume":"253","author":"Dujardin","year":"2006","journal-title":"J. Neurol."},{"key":"10.1016\/j.neuropharm.2021.108880_bib30","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1515\/REVNEURO.2007.18.1.37","article-title":"Insights into the role of dopamine receptor systems in learning and memory","volume":"18","author":"El-Ghundi","year":"2007","journal-title":"Rev. Neurosci."},{"key":"10.1016\/j.neuropharm.2021.108880_bib31","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1111\/j.1468-1331.2009.02707.x","article-title":"Cognitive function in early Parkinson's disease: a population-based study","volume":"16","author":"Elgh","year":"2009","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.neuropharm.2021.108880_bib32","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1002\/mds.27488","article-title":"Pimavanserin for Parkinson's Disease psychosis: effects stratified by baseline cognition and use of cognitive-enhancing medications","volume":"33","author":"Espay","year":"2018","journal-title":"Mov. Disord.: official journal of the Movement Disorder Society"},{"key":"10.1016\/j.neuropharm.2021.108880_bib33","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1002\/mds.26048","article-title":"Norepinephrine deficiency in Parkinson's disease: the case for noradrenergic enhancement","volume":"29","author":"Espay","year":"2014","journal-title":"Mov. Disord. : official journal of the Movement Disorder Society"},{"key":"10.1016\/j.neuropharm.2021.108880_bib34","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1007\/s00213-006-0404-5","article-title":"Mesocortical dopamine modulation of executive functions: beyond working memory","volume":"188","author":"Floresco","year":"2006","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.neuropharm.2021.108880_bib35","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1007\/s11682-014-9338-4","article-title":"Anterior cingulate dopamine turnover and behavior change in Parkinson's disease","volume":"9","author":"Gallagher","year":"2015","journal-title":"Brain imaging and behavior"},{"key":"10.1016\/j.neuropharm.2021.108880_bib36","doi-asserted-by":"crossref","first-page":"374","DOI":"10.3389\/fnins.2016.00374","article-title":"Pramipexole impairs stimulus-response learning in healthy young adults","volume":"10","author":"Gallant","year":"2016","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.neuropharm.2021.108880_bib37","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1212\/WNL.0b013e3182574fa1","article-title":"COMT Val158Met genotype influences neurodegeneration within dopamine-innervated brain structures","volume":"78","author":"Gennatas","year":"2012","journal-title":"Neurology"},{"key":"10.1016\/j.neuropharm.2021.108880_bib38","first-page":"4853590","article-title":"Atomoxetine does not improve complex attention in idiopathic Parkinson's disease patients with cognitive deficits: a meta-analysis","author":"Ghosh","year":"2020","journal-title":"Parkinson's disease 2020"},{"key":"10.1016\/j.neuropharm.2021.108880_bib39","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1093\/cercor\/bhh202","article-title":"Mice lacking dopamine D2 and D3 receptors exhibit differential activation of prefrontal cortical neurons during tasks requiring attention","volume":"15","author":"Glickstein","year":"2005","journal-title":"Cerebr. Cortex"},{"key":"10.1016\/j.neuropharm.2021.108880_bib40","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s11940-013-0281-2","article-title":"Treatment of psychosis and dementia in Parkinson's disease","volume":"16","author":"Goldman","year":"2014","journal-title":"Curr. Treat. Options Neurol."},{"key":"10.1016\/j.neuropharm.2021.108880_bib41","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1002\/mds.26352","article-title":"Advances in the treatment of cognitive impairment in Parkinson's disease","volume":"30","author":"Goldman","year":"2015","journal-title":"Mov. Disord. : official journal of the Movement Disorder Society"},{"issue":"Pt 2","key":"10.1016\/j.neuropharm.2021.108880_bib42","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1093\/brain\/111.2.299","article-title":"Frontal' cognitive function in patients with Parkinson's disease 'on' and 'off' levodopa","volume":"111","author":"Gotham","year":"1988","journal-title":"Brain : J. Neurol."},{"issue":"Suppl. l","key":"10.1016\/j.neuropharm.2021.108880_bib43","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/0924-977X(95)00030-S","article-title":"The dopamine D3 receptor and schizophrenia: pharmacological, anatomical and genetic approaches","volume":"5","author":"Griffon","year":"1995","journal-title":"Eur. Neuropsychopharmacol : the journal of the European College of Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2021.108880_bib44","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1093\/cercor\/2.6.513","article-title":"Attention and sentence processing deficits in Parkinson's disease: the role of anterior cingulate cortex","volume":"2","author":"Grossman","year":"1992","journal-title":"Cerebr. Cortex"},{"key":"10.1016\/j.neuropharm.2021.108880_bib45","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.cortex.2017.05.020","article-title":"Normal aging and Parkinson's disease are associated with the functional decline of distinct frontal-striatal circuits","volume":"93","author":"Gruszka","year":"2017","journal-title":"Cortex"},{"key":"10.1016\/j.neuropharm.2021.108880_bib46","first-page":"60","volume":"vol. 20","author":"Gurevich","year":"1999"},{"key":"10.1016\/j.neuropharm.2021.108880_bib47","doi-asserted-by":"crossref","first-page":"3025","DOI":"10.1093\/brain\/awu251","article-title":"Dopamine transporter SLC6A3 genotype affects cortico-striatal activity of set-shifts in Parkinson's disease","volume":"137","author":"Habak","year":"2014","journal-title":"Brain : J. Neurol."},{"key":"10.1016\/j.neuropharm.2021.108880_bib48","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.neuroscience.2014.09.037","article-title":"GABA-mediated changes in inter-hemispheric beta frequency activity in early-stage Parkinson's disease","volume":"281","author":"Hall","year":"2014","journal-title":"Neuroscience"},{"key":"10.1016\/j.neuropharm.2021.108880_bib49","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1002\/mds.25857","article-title":"The neurobiological basis of cognitive impairment in Parkinson's disease","volume":"29","author":"Halliday","year":"2014","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neuropharm.2021.108880_bib50","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1002\/ana.410270405","article-title":"Neuropathology of immunohistochemically identified brainstem neurons in Parkinson's disease","volume":"27","author":"Halliday","year":"1990","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.neuropharm.2021.108880_bib51","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1002\/mds.21956","article-title":"The Sydney multicenter study of Parkinson's disease: the inevitability of dementia at 20 years","volume":"23","author":"Hely","year":"2008","journal-title":"Mov. Disord. : official journal of the Movement Disorder Society"},{"key":"10.1016\/j.neuropharm.2021.108880_bib52","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1111\/j.1600-0404.1986.tb03257.x","article-title":"Cognitive performance in early Parkinson's disease","volume":"73","author":"Hietanen","year":"1986","journal-title":"Acta Neurol. Scand."},{"key":"10.1016\/j.neuropharm.2021.108880_bib53","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1002\/mdc3.12455","article-title":"A randomized clinical trial of atomoxetine for mild cognitive impairment in Parkinson's disease","volume":"4","author":"Hinson","year":"2017","journal-title":"Movement disorders clinical practice"},{"key":"10.1016\/j.neuropharm.2021.108880_bib54","doi-asserted-by":"crossref","first-page":"5976","DOI":"10.1073\/pnas.84.16.5976","article-title":"Neuronal loss in the pedunculopontine tegmental nucleus in Parkinson disease and in progressive supranuclear palsy","volume":"84","author":"Hirsch","year":"1987","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.neuropharm.2021.108880_bib55","doi-asserted-by":"crossref","DOI":"10.1093\/brain\/awab111","article-title":"The role of noradrenaline in cognition and cognitive disorders","author":"Holland","year":"2021","journal-title":"Brain : J. Neurol."},{"key":"10.1016\/j.neuropharm.2021.108880_bib56","doi-asserted-by":"crossref","first-page":"91","DOI":"10.3389\/fpsyt.2018.00091","article-title":"Medications used for cognitive enhancement in patients with schizophrenia, bipolar disorder, alzheimer's disease, and Parkinson's disease","volume":"9","author":"Hsu","year":"2018","journal-title":"Front. Psychiatr."},{"key":"10.1016\/j.neuropharm.2021.108880_bib57","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1017\/S1041610212000749","article-title":"Cognition, coping, and outcome in Parkinson's disease","volume":"24","author":"Hurt","year":"2012","journal-title":"Int. Psychogeriatr."},{"key":"10.1016\/j.neuropharm.2021.108880_bib58","doi-asserted-by":"crossref","first-page":"648","DOI":"10.3389\/fpsyg.2020.00648","article-title":"Technologies for cognitive training and cognitive rehabilitation for people with mild cognitive impairment and dementia. A systematic review","volume":"11","author":"Irazoki","year":"2020","journal-title":"Front. Psychol."},{"key":"10.1016\/j.neuropharm.2021.108880_bib59","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S0301-0082(03)00085-6","article-title":"Dopamine: a potential substrate for synaptic plasticity and memory mechanisms","volume":"69","author":"Jay","year":"2003","journal-title":"Prog. Neurobiol."},{"issue":"Suppl. 1","key":"10.1016\/j.neuropharm.2021.108880_bib60","doi-asserted-by":"crossref","first-page":"S28","DOI":"10.1016\/j.parkreldis.2020.09.022","article-title":"Can adenosine A2A receptor antagonists be used to treat cognitive impairment, depression or excessive sleepiness in Parkinson's disease?","volume":"80","author":"Jenner","year":"2020","journal-title":"Park. Relat. Disord."},{"key":"10.1016\/j.neuropharm.2021.108880_bib61","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.parkreldis.2008.03.005","article-title":"Impaired cognitive performance in Parkinson's disease is related to caudate dopaminergic hypofunction and hippocampal atrophy","volume":"15","author":"Jokinen","year":"2009","journal-title":"Park. Relat. Disord."},{"key":"10.1016\/j.neuropharm.2021.108880_bib62","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/S1353-8020(00)00060-2","article-title":"Ventral striatal D(3) receptors and Parkinson's Disease","volume":"7","author":"Joyce","year":"2001","journal-title":"Park. Relat. Disord."},{"key":"10.1016\/j.neuropharm.2021.108880_bib63","first-page":"4329297","article-title":"Effects of subthalamic nucleus deep brain stimulation on facial emotion recognition in Parkinson's disease: a critical literature review","author":"Kalampokini","year":"2020","journal-title":"Behavioural neurology 2020"},{"key":"10.1016\/j.neuropharm.2021.108880_bib64","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.arr.2014.02.004","article-title":"The impact of cognitive training and mental stimulation on cognitive and everyday functioning of healthy older adults: a systematic review and meta-analysis","volume":"15","author":"Kelly","year":"2014","journal-title":"Ageing Res. Rev."},{"key":"10.1016\/j.neuropharm.2021.108880_bib65","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1093\/ijnp\/pyx096","article-title":"NYX-2925 is a novel NMDA receptor-specific spirocyclic-beta-lactam that modulates synaptic plasticity processes associated with learning and memory","volume":"21","author":"Khan","year":"2018","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.neuropharm.2021.108880_bib66","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1097\/MNM.0000000000001098","article-title":"Association of striatal dopaminergic neuronal integrity with cognitive dysfunction and cerebral cortical metabolism in Parkinson's disease with mild cognitive impairment","volume":"40","author":"Kim","year":"2019","journal-title":"Nucl. Med. Commun."},{"key":"10.1016\/j.neuropharm.2021.108880_bib67","doi-asserted-by":"crossref","first-page":"8692","DOI":"10.1021\/jm500572b","article-title":"Medicinal chemistry of catechol O-methyltransferase (COMT) inhibitors and their therapeutic utility","volume":"57","author":"Kiss","year":"2014","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.neuropharm.2021.108880_bib68","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1002\/hbm.22006","article-title":"Prefrontal dopaminergic receptor abnormalities and executive functions in Parkinson's disease","volume":"34","author":"Ko","year":"2013","journal-title":"Hum. Brain Mapp."},{"key":"10.1016\/j.neuropharm.2021.108880_bib69","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.neuropharm.2016.07.012","article-title":"An evaluation of istradefylline treatment on Parkinsonian motor and cognitive deficits in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated macaque models","volume":"110","author":"Ko","year":"2016","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2021.108880_bib70","doi-asserted-by":"crossref","first-page":"180","DOI":"10.3389\/fnagi.2014.00180","article-title":"Effects of combined MAO-B inhibitors and levodopa vs. monotherapy in Parkinson's disease","volume":"6","author":"Krishna","year":"2014","journal-title":"Front. Aging Neurosci."},{"key":"10.1016\/j.neuropharm.2021.108880_bib71","doi-asserted-by":"crossref","first-page":"365","DOI":"10.2165\/00002512-200016050-00006","article-title":"Role of dopamine in learning and memory: implications for the treatment of cognitive dysfunction in patients with Parkinson's disease","volume":"16","author":"Kulisevsky","year":"2000","journal-title":"Drugs Aging"},{"key":"10.1016\/j.neuropharm.2021.108880_bib72","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1111\/j.1471-4159.1993.tb05838.x","article-title":"Altered muscarinic and nicotinic receptor densities in cortical and subcortical brain regions in Parkinson's disease","volume":"60","author":"Lange","year":"1993","journal-title":"J. Neurochem."},{"key":"10.1016\/j.neuropharm.2021.108880_bib73","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1007\/s00213-004-2096-z","article-title":"Dopamine D3 receptor antagonists improve the learning performance in memory-impaired rats","volume":"179","author":"Laszy","year":"2005","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.neuropharm.2021.108880_bib74","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1177\/1545968317712468","article-title":"Cognitive training and noninvasive brain stimulation for cognition in Parkinson's disease: a meta-analysis","volume":"31","author":"Lawrence","year":"2017","journal-title":"Neurorehabilitation Neural Repair"},{"key":"10.1016\/j.neuropharm.2021.108880_bib75","first-page":"4318475","article-title":"Cognitive training and transcranial direct current stimulation for mild cognitive impairment in Parkinson's disease: a randomized controlled trial","author":"Lawrence","year":"2018","journal-title":"Parkinson's disease 2018"},{"key":"10.1016\/j.neuropharm.2021.108880_bib76","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1016\/j.parkreldis.2014.07.004","article-title":"Severity of mild cognitive impairment in early Parkinson's disease contributes to poorer quality of life","volume":"20","author":"Lawson","year":"2014","journal-title":"Park. Relat. Disord."},{"key":"10.1016\/j.neuropharm.2021.108880_bib77","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1002\/gps.4623","article-title":"Cognitive impairment in Parkinson's disease: impact on quality of life of carers","volume":"32","author":"Lawson","year":"2017","journal-title":"Int. J. Geriatr. Psychiatr."},{"issue":"Pt 2","key":"10.1016\/j.neuropharm.2021.108880_bib78","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1093\/brain\/106.2.257","article-title":"Cognitive deficits in the early stages of Parkinson's disease","volume":"106","author":"Lees","year":"1983","journal-title":"Brain : J. Neurol."},{"key":"10.1016\/j.neuropharm.2021.108880_bib79","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1212\/WNL.0000000000002145","article-title":"Cognitive training in Parkinson disease: a systematic review and meta-analysis","volume":"85","author":"Leung","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.neuropharm.2021.108880_bib80","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1002\/mds.23823","article-title":"MDS Task Force on mild cognitive impairment in Parkinson's disease: critical review of PD-MCI. Movement disorders","volume":"26","author":"Litvan","year":"2011","journal-title":"official journal of the Movement Disorder Society"},{"key":"10.1016\/j.neuropharm.2021.108880_bib81","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1002\/mds.24893","article-title":"Diagnostic criteria for mild cognitive impairment in Parkinson's disease: movement Disorder Society Task Force guidelines","volume":"27","author":"Litvan","year":"2012","journal-title":"Mov. Disord. : official journal of the Movement Disorder Society"},{"key":"10.1016\/j.neuropharm.2021.108880_bib82","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1007\/s00228-009-0658-z","article-title":"Association of the DRD2 and DRD3 polymorphisms with response to pramipexole in Parkinson's disease patients","volume":"65","author":"Liu","year":"2009","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.neuropharm.2021.108880_bib83","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1002\/mds.26236","article-title":"Rivastigmine for mild cognitive impairment in Parkinson disease: a placebo-controlled study","volume":"30","author":"Mamikonyan","year":"2015","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neuropharm.2021.108880_bib84","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1001\/jamaneurol.2018.2820","article-title":"Patterns of dementia treatment and frank prescribing errors in older adults with Parkinson disease","volume":"76","author":"Mantri","year":"2019","journal-title":"JAMA neurology"},{"key":"10.1016\/j.neuropharm.2021.108880_bib85","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1002\/mds.22307","article-title":"Atomoxetine for the treatment of executive dysfunction in Parkinson's disease: a pilot open-label study","volume":"24","author":"Marsh","year":"2009","journal-title":"Mov. Disord. : official journal of the Movement Disorder Society"},{"key":"10.1016\/j.neuropharm.2021.108880_bib86","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.neuropharm.2019.01.003","article-title":"Selective activation of Dopamine D3 receptors and norepinephrine transporter blockade enhances sustained attention","volume":"148","author":"Marshall","year":"2019","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2021.108880_bib87","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1002\/mds.27898","article-title":"The anterior caudate nucleus supports impulsive choices triggered by pramipexole","volume":"35","author":"Martinez","year":"2020","journal-title":"Mov. Disord. : official journal of the Movement Disorder Society"},{"key":"10.1016\/j.neuropharm.2021.108880_bib88","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1017\/S1461145710000775","article-title":"The dopamine D3 receptor antagonist, S33138, counters cognitive impairment in a range of rodent and primate procedures","volume":"13","author":"Millan","year":"2010","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.neuropharm.2021.108880_bib89","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1111\/j.1471-4159.2006.04262.x","article-title":"Selective blockade of dopamine D(3) versus D(2) receptors enhances frontocortical cholinergic transmission and social memory in rats: a parallel neurochemical and behavioural analysis","volume":"100","author":"Millan","year":"2007","journal-title":"J. Neurochem."},{"key":"10.1016\/j.neuropharm.2021.108880_bib90","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1146\/annurev.neuro.24.1.167","article-title":"An integrative theory of prefrontal cortex function","volume":"24","author":"Miller","year":"2001","journal-title":"Annu. Rev. Neurosci."},{"key":"10.1016\/j.neuropharm.2021.108880_bib91","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1136\/jnnp.50.9.1192","article-title":"Cognitive concomitants of dopamine system stimulation in parkinsonian patients","volume":"50","author":"Mohr","year":"1987","journal-title":"J. Neurol. Neurosurg. Psychiatr."},{"key":"10.1016\/j.neuropharm.2021.108880_bib92","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1007\/s00702-020-02255-2","article-title":"Transcranial random noise stimulation over the primary motor cortex in PD-MCI patients: a crossover, randomized, sham-controlled study","volume":"127","author":"Monastero","year":"2020","journal-title":"J. Neural. Transm."},{"key":"10.1016\/j.neuropharm.2021.108880_bib93","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/B978-0-12-801022-8.00004-0","article-title":"Mode of action of adenosine A2A receptor antagonists as symptomatic treatment for Parkinson's disease","volume":"119","author":"Mori","year":"2014","journal-title":"Int. Rev. Neurobiol."},{"key":"10.1016\/j.neuropharm.2021.108880_bib94","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1136\/jnnp.51.6.757","article-title":"Planning and spatial working memory in Parkinson's disease","volume":"51","author":"Morris","year":"1988","journal-title":"J. Neurol. Neurosurg. Psychiatr."},{"key":"10.1016\/j.neuropharm.2021.108880_bib95","doi-asserted-by":"crossref","first-page":"3282","DOI":"10.1093\/brain\/awt247","article-title":"Thalamic cholinergic innervation and postural sensory integration function in Parkinson's disease","volume":"136","author":"Muller","year":"2013","journal-title":"Brain : J. Neurol."},{"key":"10.1016\/j.neuropharm.2021.108880_bib96","doi-asserted-by":"crossref","first-page":"11271","DOI":"10.1073\/pnas.91.23.11271","article-title":"Localization of dopamine D3 receptors to mesolimbic and D2 receptors to mesostriatal regions of human forebrain","volume":"91","author":"Murray","year":"1994","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.neuropharm.2021.108880_bib97","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.neurobiolaging.2013.06.025","article-title":"Effect of mild cognitive impairment on the patterns of neural activity in early Parkinson's disease","volume":"35","author":"Nagano-Saito","year":"2014","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.neuropharm.2021.108880_bib98","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/j.euroneuro.2013.05.006","article-title":"The potential role of dopamine D(3) receptor neurotransmission in cognition","volume":"23","author":"Nakajima","year":"2013","journal-title":"Eur. Neuropsychopharmacol : the journal of the European College of Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2021.108880_bib99","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1515\/revneuro-2013-0004","article-title":"Prefrontal dopamine signaling and cognitive symptoms of Parkinson's disease","volume":"24","author":"Narayanan","year":"2013","journal-title":"Rev. Neurosci."},{"key":"10.1016\/j.neuropharm.2021.108880_bib100","doi-asserted-by":"crossref","first-page":"21","DOI":"10.3389\/fnagi.2019.00021","article-title":"Incidence of mild cognitive impairment and dementia in Parkinson's disease: the Parkinson's disease cognitive impairment study","volume":"11","author":"Nicoletti","year":"2019","journal-title":"Front. Aging Neurosci."},{"key":"10.1016\/j.neuropharm.2021.108880_bib101","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1007\/s00259-011-1874-1","article-title":"Brain perfusion correlates of cognitive and nigrostriatal functions in de novo Parkinson's disease","volume":"38","author":"Nobili","year":"2011","journal-title":"Eur. J. Nucl. Med. Mol. Imag."},{"key":"10.1016\/j.neuropharm.2021.108880_bib102","doi-asserted-by":"crossref","DOI":"10.1093\/brain\/awab142","article-title":"Locus coeruleus integrity and the effect of atomoxetine on response inhibition in Parkinson's disease","author":"O'Callaghan","year":"2021","journal-title":"Brain : J. Neurol."},{"key":"10.1016\/j.neuropharm.2021.108880_bib103","doi-asserted-by":"crossref","first-page":"98","DOI":"10.14802\/jmd.15041","article-title":"Effect of rivastigmine on behavioral and psychiatric symptoms of Parkinson's disease dementia","volume":"8","author":"Oh","year":"2015","journal-title":"Journal of movement disorders"},{"key":"10.1016\/j.neuropharm.2021.108880_bib104","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.pneurobio.2015.09.005","article-title":"New insight into the therapeutic role of the serotonergic system in Parkinson's disease","volume":"134","author":"Ohno","year":"2015","journal-title":"Prog. Neurobiol."},{"key":"10.1016\/j.neuropharm.2021.108880_bib105","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/nn1165","article-title":"Increased prefrontal and parietal activity after training of working memory","volume":"7","author":"Olesen","year":"2004","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.neuropharm.2021.108880_bib106","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.neuropsychologia.2013.10.024","article-title":"The effects of dopaminergic medication on dynamic decision making in Parkinson's disease","volume":"53","author":"Osman","year":"2014","journal-title":"Neuropsychologia"},{"issue":"Pt 6","key":"10.1016\/j.neuropharm.2021.108880_bib107","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1093\/brain\/115.6.1727","article-title":"Fronto-striatal cognitive deficits at different stages of Parkinson's disease","volume":"115","author":"Owen","year":"1992","journal-title":"Brain : J. Neurol."},{"key":"10.1016\/j.neuropharm.2021.108880_bib108","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1002\/mds.23688","article-title":"Blind randomized controlled study of the efficacy of cognitive training in Parkinson's disease","volume":"26","author":"Paris","year":"2011","journal-title":"Mov. Disord. : official journal of the Movement Disorder Society"},{"key":"10.1016\/j.neuropharm.2021.108880_bib109","doi-asserted-by":"crossref","first-page":"75","DOI":"10.3389\/fnint.2013.00075","article-title":"Executive dysfunction in Parkinson's disease and timing deficits","volume":"7","author":"Parker","year":"2013","journal-title":"Front. Integr. Neurosci."},{"key":"10.1016\/j.neuropharm.2021.108880_bib110","doi-asserted-by":"crossref","first-page":"16001","DOI":"10.1038\/npjparkd.2016.1","article-title":"Deficits in cholinergic neurotransmission and their clinical correlates in Parkinson's disease","volume":"2","author":"Perez-Lloret","year":"2016","journal-title":"NPJ Parkinson's disease"},{"key":"10.1016\/j.neuropharm.2021.108880_bib111","doi-asserted-by":"crossref","first-page":"408","DOI":"10.2174\/1567205015666171212094229","article-title":"Catechol-O-methyltransferase, cognition and alzheimer's disease","volume":"15","author":"Perkovic","year":"2018","journal-title":"Curr. Alzheimer Res."},{"key":"10.1016\/j.neuropharm.2021.108880_bib112","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/0306-4522(94)00410-7","article-title":"Alteration in nicotine binding sites in Parkinson's disease, Lewy body dementia and Alzheimer's disease: possible index of early neuropathology","volume":"64","author":"Perry","year":"1995","journal-title":"Neuroscience"},{"key":"10.1016\/j.neuropharm.2021.108880_bib113","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1017\/S0317167100037240","article-title":"Cholinergic receptors in cognitive disorders","volume":"13","author":"Perry","year":"1986","journal-title":"The Canadian journal of neurological sciences Le journal canadien des sciences neurologiques"},{"key":"10.1016\/j.neuropharm.2021.108880_bib114","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1016\/j.parkreldis.2014.08.023","article-title":"Effects of cognitive training in Parkinson's disease: a randomized controlled trial","volume":"20","author":"Petrelli","year":"2014","journal-title":"Park. Relat. Disord."},{"key":"10.1016\/j.neuropharm.2021.108880_bib115","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1111\/ene.12621","article-title":"Cognitive training in Parkinson's disease reduces cognitive decline in the long term","volume":"22","author":"Petrelli","year":"2015","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.neuropharm.2021.108880_bib116","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1002\/mds.25575","article-title":"Rivastigmine is associated with restoration of left frontal brain activity in Parkinson's disease","volume":"28","author":"Possin","year":"2013","journal-title":"Mov. Disord. : official journal of the Movement Disorder Society"},{"key":"10.1016\/j.neuropharm.2021.108880_bib117","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/S0149-7634(01)00023-9","article-title":"D3 dopamine receptor, behavioral sensitization, and psychosis","volume":"25","author":"Richtand","year":"2001","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/j.neuropharm.2021.108880_bib118","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1097\/00004714-199910000-00008","article-title":"Alpha2-adrenergic agonist clonidine for improving spatial working memory in Parkinson's disease","volume":"19","author":"Riekkinen","year":"1999","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2021.108880_bib119","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/s00702-020-02259-y","article-title":"Safinamide improves executive functions in fluctuating Parkinson's disease patients: an exploratory study","volume":"128","author":"Rinaldi","year":"2021","journal-title":"J. Neural. Transm."},{"key":"10.1016\/j.neuropharm.2021.108880_bib120","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/0006-8993(91)90588-M","article-title":"A postmortem study of brain nicotinic receptors in Parkinson's and Alzheimer's disease","volume":"547","author":"Rinne","year":"1991","journal-title":"Brain Res."},{"key":"10.1016\/j.neuropharm.2021.108880_bib121","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1002\/syn.1042","article-title":"[(18)F]FDOPA and [(18)F]CFT are both sensitive PET markers to detect presynaptic dopaminergic hypofunction in early Parkinson's disease","volume":"40","author":"Rinne","year":"2001","journal-title":"Synapse"},{"key":"10.1016\/j.neuropharm.2021.108880_bib122","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1093\/brain\/awn112","article-title":"Parkinson's disease and dopaminergic therapy--differential effects on movement, reward and cognition","volume":"131","author":"Rowe","year":"2008","journal-title":"Brain : J. Neurol."},{"key":"10.1016\/j.neuropharm.2021.108880_bib123","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1017\/cjn.2018.21","article-title":"Effects of antiparkinson medication on cognition in Parkinson's disease: a systematic review","volume":"45","author":"Roy","year":"2018","journal-title":"The Canadian journal of neurological sciences Le journal canadien des sciences neurologiques"},{"key":"10.1016\/j.neuropharm.2021.108880_bib124","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1038\/tpj.2016.43","article-title":"COMT val158met moderation of dopaminergic drug effects on cognitive function: a critical review","volume":"16","author":"Schacht","year":"2016","journal-title":"Pharmacogenomics J."},{"key":"10.1016\/j.neuropharm.2021.108880_bib125","doi-asserted-by":"crossref","first-page":"113514","DOI":"10.1016\/j.expneurol.2020.113514","article-title":"A novel dopamine D3R agonist SK609 with norepinephrine transporter inhibition promotes improvement in cognitive task performance in rodent and non-human primate models of Parkinson's disease","volume":"335","author":"Schneider","year":"2021","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.neuropharm.2021.108880_bib126","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.bbr.2010.03.040","article-title":"Clonidine improves attentional and memory components of delayed response performance in a model of early Parkinsonism","volume":"211","author":"Schneider","year":"2010","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.neuropharm.2021.108880_bib127","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1124\/jpet.103.051912","article-title":"The subtype-selective nicotinic acetylcholine receptor agonist SIB-1553A improves both attention and memory components of a spatial working memory task in chronic low dose 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated monkeys","volume":"306","author":"Schneider","year":"2003","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.neuropharm.2021.108880_bib128","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/S0022-3565(24)34957-2","article-title":"Nicotinic acetylcholine receptor agonist SIB-1508Y improves cognitive functioning in chronic low-dose MPTP-treated monkeys","volume":"290","author":"Schneider","year":"1999","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.neuropharm.2021.108880_bib129","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/0304-3940(95)11367-6","article-title":"Gene expression of the nicotinic acetylcholine receptor alpha 4 subunit in the frontal cortex in Parkinson's disease patients","volume":"187","author":"Schroder","year":"1995","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.neuropharm.2021.108880_bib130","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1002\/syn.21805","article-title":"Parkinson's disease treatment may cause impulse-control disorder via dopamine D3 receptors","volume":"69","author":"Seeman","year":"2015","journal-title":"Synapse"},{"key":"10.1016\/j.neuropharm.2021.108880_bib131","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1002\/mds.27602","article-title":"Update on treatments for nonmotor symptoms of Parkinson's disease-an evidence-based medicine review","volume":"34","author":"Seppi","year":"2019","journal-title":"Mov. Disord. : official journal of the Movement Disorder Society"},{"key":"10.1016\/j.neuropharm.2021.108880_bib132","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bandc.2018.01.002","article-title":"Aerobic exercise is more effective than goal-based exercise for the treatment of cognition in Parkinson's disease","volume":"122","author":"Silveira","year":"2018","journal-title":"Brain Cognit."},{"key":"10.1016\/j.neuropharm.2021.108880_bib133","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/S0091-3057(98)00230-5","article-title":"The dopamine D3\/D2 receptor agonist 7-OH-DPAT induces cognitive impairment in the marmoset","volume":"63","author":"Smith","year":"1999","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.neuropharm.2021.108880_bib134","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/ejn.13390","article-title":"The dopamine D3 receptor, a quarter century later","volume":"45","author":"Sokoloff","year":"2017","journal-title":"Eur. J. Neurosci."},{"issue":"Pt 5","key":"10.1016\/j.neuropharm.2021.108880_bib135","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1093\/brain\/116.5.1139","article-title":"Disturbed frontal regulation of attention in Parkinson's disease","volume":"116","author":"Stam","year":"1993","journal-title":"Brain : J. Neurol."},{"key":"10.1016\/j.neuropharm.2021.108880_bib136","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S0301-0082(99)00011-8","article-title":"Distribution, biochemistry and function of striatal adenosine A2A receptors","volume":"59","author":"Svenningsson","year":"1999","journal-title":"Prog. Neurobiol."},{"key":"10.1016\/j.neuropharm.2021.108880_bib137","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/S1474-4422(12)70152-7","article-title":"Cognitive impairment in patients with Parkinson's disease: diagnosis, biomarkers, and treatment","volume":"11","author":"Svenningsson","year":"2012","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.neuropharm.2021.108880_bib138","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/S0028-3932(99)00103-7","article-title":"Probabilistic learning and reversal deficits in patients with Parkinson's disease or frontal or temporal lobe lesions: possible adverse effects of dopaminergic medication","volume":"38","author":"Swainson","year":"2000","journal-title":"Neuropsychologia"},{"key":"10.1016\/j.neuropharm.2021.108880_bib139","doi-asserted-by":"crossref","first-page":"12032","DOI":"10.1523\/JNEUROSCI.3446-08.2008","article-title":"Differential contributions of prefrontal and hippocampal dopamine D(1) and D(2) receptors in human cognitive functions","volume":"28","author":"Takahashi","year":"2008","journal-title":"J. Neurosci. : the official journal of the Society for Neuroscience"},{"key":"10.1016\/j.neuropharm.2021.108880_bib140","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1038\/jcbfm.2011.194","article-title":"Functional significance of central D1 receptors in cognition: beyond working memory","volume":"32","author":"Takahashi","year":"2012","journal-title":"J. Cerebr. Blood Flow Metabol. : official journal of the International Society of Cerebral Blood Flow and Metabolism"},{"key":"10.1016\/j.neuropharm.2021.108880_bib141","first-page":"829","article-title":"[The relationship between pathophysiology and neurotransmitters in Parkinson's disease]","volume":"73","author":"Takeda","year":"2021","journal-title":"Brain and nerve = Shinkei kenkyu no shinpo"},{"key":"10.1016\/j.neuropharm.2021.108880_bib142","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.bandc.2009.04.003","article-title":"On the role of dopamine replacement therapy in decision-making, working memory, and reward in Parkinson's disease: does the therapy-dose matter?","volume":"71","author":"Torta","year":"2009","journal-title":"Brain Cognit."},{"key":"10.1016\/j.neuropharm.2021.108880_bib143","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1002\/mds.28360","article-title":"Cholinergic denervation patterns across cognitive domains in Parkinson's disease","volume":"36","author":"van der Zee","year":"2021","journal-title":"Mov. Disord. : official journal of the Movement Disorder Society"},{"key":"10.1016\/j.neuropharm.2021.108880_bib144","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1111\/j.1755-5949.2010.00166.x","article-title":"Effects of cholinesterase inhibitors in Parkinson's disease dementia: a review of clinical data","volume":"17","author":"van Laar","year":"2011","journal-title":"CNS Neurosci. Ther."},{"key":"10.1016\/j.neuropharm.2021.108880_bib145","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1007\/s00213-006-0347-x","article-title":"Differential contributions of dopaminergic D1- and D2-like receptors to cognitive function in rhesus monkeys","volume":"188","author":"Von Huben","year":"2006","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.neuropharm.2021.108880_bib146","first-page":"311","article-title":"Association of Parkinson's disease with symptoms of attention deficit hyperactivity disorder in childhood","author":"Walitza","year":"2007","journal-title":"J. Neural. Transm. Suppl."},{"key":"10.1016\/j.neuropharm.2021.108880_bib147","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1097\/JCP.0000000000000963","article-title":"The role of atomoxetine for Parkinson disease-related executive dysfunction: a systematic review","volume":"38","author":"Warner","year":"2018","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2021.108880_bib148","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1159\/000341996","article-title":"Impulse control and related disorders in Parkinson's disease","volume":"11","author":"Weintraub","year":"2013","journal-title":"Neurodegener. Dis."},{"key":"10.1016\/j.neuropharm.2021.108880_bib149","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1093\/brain\/awm111","article-title":"Evolution of cognitive dysfunction in an incident Parkinson's disease cohort","volume":"130","author":"Williams-Gray","year":"2007","journal-title":"Brain : J. Neurol."},{"key":"10.1016\/j.neuropharm.2021.108880_bib150","first-page":"309","article-title":"Parkinson's disease: premotor clinico-pathological correlations","author":"Wolters","year":"2006","journal-title":"J. Neural. Transm. Suppl."},{"key":"10.1016\/j.neuropharm.2021.108880_bib151","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1212\/WNL.0000000000000066","article-title":"Characterizing mild cognitive impairment in incident Parkinson disease: the ICICLE-PD study","volume":"82","author":"Yarnall","year":"2014","journal-title":"Neurology"},{"key":"10.1016\/j.neuropharm.2021.108880_bib152","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2018-027062","article-title":"Effect of computerised cognitive training on cognitive outcomes in mild cognitive impairment: a systematic review and meta-analysis","volume":"9","author":"Zhang","year":"2019","journal-title":"BMJ Open"},{"key":"10.1016\/j.neuropharm.2021.108880_bib153","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1007\/s13311-020-00963-x","article-title":"Approach to cognitive impairment in Parkinson's disease","volume":"17","author":"Zhang","year":"2020","journal-title":"Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics"},{"key":"10.1016\/j.neuropharm.2021.108880_bib154","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.jns.2016.08.063","article-title":"Catechol-O-methyltransferase Val158Met polymorphism influences prefrontal executive function in early Parkinson's disease","volume":"369","author":"Zhang","year":"2016","journal-title":"J. Neurol. Sci."}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390821004354?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390821004354?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T07:15:44Z","timestamp":1758438944000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390821004354"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":154,"alternative-id":["S0028390821004354"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2021.108880","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2022,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Current concepts in treating mild cognitive impairment in Parkinson's disease","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2021.108880","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"108880"}}